Azacitidine

Prostate Neoplasms

Icahn School of Medicine at Mount SinaiSmall moleculePhase 2Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 95/ 100

Competitive context

4 Active assets in the Prostate Neoplasms cohort.

Asset / Sponsor	Phase	Rating
Zoladex Wonju Severance Christian Hospital	Phase 4	BB
Bortezomib Millennium Pharmaceuticals, Inc.	Phase 2	BB
FLUDEOXYGLUCOSE National Cancer Institute (NCI)	Phase 2	B
17-beta-estradiol University of Washington	Phase 2	B
AVOLVE CHU de Quebec-Universite Laval	Phase 2	B

View all 16 →

Same molecule, other indications

Azacitidine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant

BBB

Indicative ·

73 / 100

acute erythroid leukemiaDormant

BB

Indicative ·

71 / 100

non-small cell lung carcinomaDormant

BB

Indicative ·

71 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.